{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"LGND","limit":50},"count":50,"signals":[{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":94,"context":", result in delays, the suspension of regulatory approvals, regulatory enforcement actions, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners.  In particular, FDA approval is required before a drug or biological product may be marketed in the United States, and these products are also subject to other federal, state,","filed_date":"2026-02-27","accession":"0000886163-26-000006","full_text":"https://origin.rootz.global/static/filing/0000886163-26-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"December 31, 2025, we recognized a full impairment of all Agenus partner programs, including UGN-301 which was returned to Agenus by Urogen in the fourth quarter of 2025.88TzieldIn November 2023, we acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics was a holding company, owned by the inventors of Tzield (teplizumab), and is owed a royalty of less than 1% on worldwide net sales of Tzield. Tzield is marke","filed_date":"2026-02-27","accession":"0000886163-26-000006","full_text":"https://origin.rootz.global/static/filing/0000886163-26-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"5-07.All Agenus program financial royalty assets are accounted for using the non-accrual method as management cannot reliably estimate future cash flows from these programs.TzieldIn November 2023, we acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics was a holding company, owned by the inventors of Tzield (teplizumab), and is owed a royalty of less than 1% on worldwide net sales of Tzield. Tzield is marke","filed_date":"2025-11-07","accession":"0000886163-25-000063","full_text":"https://origin.rootz.global/static/filing/0000886163-25-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":47,"context":"Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (except, if a qualifier relating to materiality, Material Adverse Effect or a similar concept applies, such representation or warranty is true and correct in all respects), except to the extent that such representations and warranties specifically refer to an earlier date","filed_date":"2025-09-16","accession":"0001193125-25-205147","full_text":"https://origin.rootz.global/static/filing/0001193125-25-205147.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"Acquisition effective date. We account for InvIOs financial royalty assets using the non-accrual method until we are able to reliably estimate future cash flows.23Tzield AgreementIn November 2023, we acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics was a holding company, owned by the inventors of Tzield (teplizumab), and is owed a royalty of less than 1% on worldwide net sales of Tzield. Tzield is marke","filed_date":"2025-08-08","accession":"0000886163-25-000051","full_text":"https://origin.rootz.global/static/filing/0000886163-25-000051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":121,"context":"2.To ratify the selection of Ernst & Young LLP as our independent registered accounting firm for the fiscal year ending December 31, 2025. 3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement. 4.To transact such other business as may properly come before the meeting or any adjournment(s) thereof. Stockholders of record at the close of business on the","filed_date":"2025-04-22","accession":"0000886163-25-000025","full_text":"https://origin.rootz.global/static/filing/0000886163-25-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":76,"context":", result in delays, the suspension of regulatory approvals, regulatory enforcement actions, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners.  14 In particular, FDA approval is required before a drug or biological product may be marketed in the United States, and these products are also subject to other federal, stat","filed_date":"2025-02-28","accession":"0000886163-25-000012","full_text":"https://origin.rootz.global/static/filing/0000886163-25-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"Acquisition effective date. We accounted for InvIOs financial royalty assets using the non-accrual method until we are able to reliably estimate future cash flows.Tzield AgreementIn November 2023, we acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of Tzield (teplizumab), and is owed a royalty of less than 1% on worldwide net sales of Tzield. Tzield is market","filed_date":"2025-02-28","accession":"0000886163-25-000012","full_text":"https://origin.rootz.global/static/filing/0000886163-25-000012.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":122,"context":"2.To ratify the selection of Ernst & Young LLP as our independent registered accounting firm for the fiscal year ending December 31, 2024. 3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement. 4.To approve an amendment and restatement of the Companys 2002 Stock Incentive Plan. 5.To transact such other business as may properly come before the meeting o","filed_date":"2024-04-25","accession":"0000886163-24-000020","full_text":"https://origin.rootz.global/static/filing/0000886163-24-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":68,"context":"sult in delays, the suspension of regulatory approvals, regulatory enforcement  16 actions, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners.  In particular, FDA approval is required before a drug or biological product may be marketed in the United States and they are also subject to other federal, state, and local s","filed_date":"2024-02-29","accession":"0000886163-24-000009","full_text":"https://origin.rootz.global/static/filing/0000886163-24-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"ed the existing commercial royalties related to the Pelican Expression Technology platform and owns 49.9% of Primrose Bio. We also entered into a purchase and sale agreement with Primrose, whereby we invested $15 million in exchange for a portion of the economic rights from the two existing contracts of Primordial Genetics and an economic interest in potential future revenues generated from the Pelican business. Liga","filed_date":"2024-02-29","accession":"0000886163-24-000009","full_text":"https://origin.rootz.global/static/filing/0000886163-24-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":45,"context":"Qualification and Power. | 79 | | | 5.02Authorization No Contravention. | 79 | | | 5.03Governmental Authorization Other Consents. | 80 | | | 5.04Binding Effect. | 80 | | | 5.05Financial Statements No Material Adverse Effect. | 80 | | | 5.06Litigation. | 81 | | | 5.07No Default. | 81 | | | 5.08Ownership of Property. | 81 | | | 5.09Environmental Matters. | 81 | | | 5.10Insurance. | 81 | | | 5.11Taxes. | 82 | | | 5.12ERISA","filed_date":"2023-10-18","accession":"0000886163-23-000075","full_text":"https://origin.rootz.global/static/filing/0000886163-23-000075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":152,"context":"e selection of Ernst & Young LLP as our independent registered accounting firm for the fiscal year ending December 31, 2023. 3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission. 4.To consider and vote upon, on an advisory basis, whether the stockhold","filed_date":"2023-04-20","accession":"0000886163-23-000018","full_text":"https://origin.rootz.global/static/filing/0000886163-23-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2023-02-28","accession":"0000886163-23-000007","full_text":"https://origin.rootz.global/static/filing/0000886163-23-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"from their positions with us upon the completion of the Separation to join management positions with New OmniAb. In connection with the Separation and the departure of the foregoing officers, Ligand appointed new officers. Matthew Korenberg, our former Executive Vice President, Finance and Chief Financial Officer, was appointed our President and Chief Operating Officer. Octavio Espinoza, our former Senior Vice Presid","filed_date":"2023-02-28","accession":"0000886163-23-000007","full_text":"https://origin.rootz.global/static/filing/0000886163-23-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"from their positions with us upon the completion of the Separation to join management positions with OmniAb, Inc. In connection with the Separation and the departure of the foregoing officers, Ligand appointed new officers. Matthew Korenberg, our former Executive Vice President, Finance and Chief Financial Officer, was appointed our President and Chief Operating Officer. Octavio Espinoza, our former Senior Vice Presid","filed_date":"2022-11-08","accession":"0000886163-22-000135","full_text":"https://origin.rootz.global/static/filing/0000886163-22-000135.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":114,"context":"the selection of Ernst Young LLP as our independent registered accounting firm for the fiscal year ending December 31, 2022. 3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the SEC). 4.To approve an amendment and restatement of the Companys 2002","filed_date":"2022-04-22","accession":"0000886163-22-000038","full_text":"https://origin.rootz.global/static/filing/0000886163-22-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":57,"context":"re Schedule delivered by the Company to Parent on the date hereof and identified as such.  (26) Company Equity Award has the meaning given to such term in the Employee Matters Agreement. (27) Company Material Adverse Effect means any Effect that has, or would reasonably be expected to, individually or in the aggregate, materially impair, materially delay or otherwise have a material adverse effect on the ability of the","filed_date":"2022-03-24","accession":"0001193125-22-083443","full_text":"https://origin.rootz.global/static/filing/0001193125-22-083443.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"ation.  Section 2.5 Governance Matters.  (a) The Parties shall use reasonable best efforts to ensure that the individuals listed on Section 2.5(a) of the Company Disclosure Schedule are nominated and elected as directors of Parent effective immediately after the Closing, and the identities of such individuals shall be made publicly available as promptly as practicable following the date hereof (but in any event prio","filed_date":"2022-03-24","accession":"0001193125-22-083443","full_text":"https://origin.rootz.global/static/filing/0001193125-22-083443.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2022-02-28","accession":"0000886163-22-000030","full_text":"https://origin.rootz.global/static/filing/0000886163-22-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":109,"context":"the selection of Ernst Young LLP as our independent registered accounting firm for the fiscal year ending December 31, 2021. 3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the SEC). 4.To transact such other business as may properly come before","filed_date":"2021-04-23","accession":"0000886163-21-000058","full_text":"https://origin.rootz.global/static/filing/0000886163-21-000058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2021-02-24","accession":"0000886163-21-000050","full_text":"https://origin.rootz.global/static/filing/0000886163-21-000050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":103,"context":"on. As part of the TCJA, the ability to rely on this exemption was, with certain limited exceptions, eliminated; in addition, the definition of covered employees was expanded to generally include all named executive officers. Certain awards under the Existing Plan granted prior to November 2, 2017 may be grandfathered from the changes made by the TCJA under certain limited transition relief, however, for grants after th","filed_date":"2020-11-12","accession":"0001193125-20-291679","full_text":"https://origin.rootz.global/static/filing/0001193125-20-291679.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"rketable securities and short-term investments), in each case determined in accordance with GAAP. Company Common Stock means the common stock, par value $0.00003333 per share, of the Company. Company Material Adverse Effect means any change, effect, event, occurrence, development, matter, state of facts, series of events, or circumstance (any such item, an Effect) that, individually or in the aggregate with all other Ef","filed_date":"2020-09-10","accession":"0000886163-20-000101","full_text":"https://origin.rootz.global/static/filing/0000886163-20-000101.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":113,"context":"the selection of Ernst Young LLP as our independent registered accounting firm for the fiscal year ending December 31, 2020. 3.To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the SEC). 4.To transact such other business as may properly come before","filed_date":"2020-04-24","accession":"0000886163-20-000045","full_text":"https://origin.rootz.global/static/filing/0000886163-20-000045.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2020-02-27","accession":"0000886163-20-000025","full_text":"https://origin.rootz.global/static/filing/0000886163-20-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"on the option grant date, and no granted option will have a term in excess of 10 years. The shares subject to each option will generally become exercisable for fully-vested shares in a series of installments over a specified period of service measured from the grant date. However, one or more options may be structured so that they are immediately exercisable for any or all of the option shares. The s","filed_date":"2019-04-24","accession":"0000886163-19-000063","full_text":"https://origin.rootz.global/static/filing/0000886163-19-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":119,"context":"ng LLP as the Companys independent registered accounting firm for the fiscal year ending December 31, 2019. | | | | | | | 3. | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the \"SEC\"). | | | | | | | 4. | To approve the amendment and restatement","filed_date":"2019-04-24","accession":"0000886163-19-000063","full_text":"https://origin.rootz.global/static/filing/0000886163-19-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2019-02-28","accession":"0000886163-19-000041","full_text":"https://origin.rootz.global/static/filing/0000886163-19-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"oducts will progress in their development, gain marketing approval or achieve success in the market.In addition, ongoing or future arbitration, or litigation or disputes with third parties may have a material adverse effect on us. Such risks and uncertainties, and others, could cause actual results to differ materially from any future performance suggested. We undertake no obligation to make any revisions to these forwa","filed_date":"2018-11-08","accession":"0000886163-18-000162","full_text":"https://origin.rootz.global/static/filing/0000886163-18-000162.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"oducts will progress in their development, gain marketing approval or achieve success in the market.In addition, ongoing or future arbitration, or litigation or disputes with third parties may have a material adverse effect on us. Such risks and uncertainties, and others, could cause actual results to differ materially from any future performance suggested. We undertake no obligation to make any revisions to these forwa","filed_date":"2018-08-08","accession":"0000886163-18-000113","full_text":"https://origin.rootz.global/static/filing/0000886163-18-000113.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":114,"context":"ng LLP as the Companys independent registered accounting firm for the fiscal year ending December 31, 2018. | | | | | | | 3. | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the \"SEC\"). | | | | | | | 4. | To transact such other business as may pr","filed_date":"2018-04-30","accession":"0000886163-18-000056","full_text":"https://origin.rootz.global/static/filing/0000886163-18-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2018-03-01","accession":"0000886163-18-000030","full_text":"https://origin.rootz.global/static/filing/0000886163-18-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"nalties, Taxes, costs and expenses (including reasonable attorneys fees and expenses and costs of investigation), whether involving a third-party claim or a claim solely between the parties hereto. 49Material Adverse Effect when used in connection with an entity, shall mean any change or effect that has occurred prior to the date of determination of the occurrence of the Material Adverse Effect, that is materially adver","filed_date":"2017-10-04","accession":"0000886163-17-000114","full_text":"https://origin.rootz.global/static/filing/0000886163-17-000114.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":116,"context":"ng LLP as the Companys independent registered accounting firm for the fiscal year ending December 31, 2017. | | | | | | | 3. | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the \"SEC\"). | | | | | | | 4. | To consider and vote upon, on an advisory","filed_date":"2017-04-14","accession":"0000886163-17-000049","full_text":"https://origin.rootz.global/static/filing/0000886163-17-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2016-11-14","accession":"0000886163-16-000239","full_text":"https://origin.rootz.global/static/filing/0000886163-16-000239.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"on the option grant date, and no granted option will have a term in excess of 10 years. The shares subject to each option will generally become exercisable for fully-vested shares in a series of installments over a specified period of service measured from the grant date. However, one or more options may be structured so that  Ligand Pharmaceuticals Incorporated 2016 Proxy Statement l17 they are imme","filed_date":"2016-04-12","accession":"0000886163-16-000164","full_text":"https://origin.rootz.global/static/filing/0000886163-16-000164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":110,"context":"ootprint. | | | | | | | | Research and Development: In 2015, the Company continued to advance its product pipeline, including the receipt of positive Phase 1b Glucagon data. Additionally, the Company completed a licensing agreement for oral lasofoxifene to Sermonix and acquired rights to more than 15 biologic Shots-on-Goal from proof of concept studies completed by Selexis. | | | | | | | | Operational Achievements: During 2015,","filed_date":"2016-04-12","accession":"0000886163-16-000164","full_text":"https://origin.rootz.global/static/filing/0000886163-16-000164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"irements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under Item 1A. Risk Factors. Patents and Proprietary Rights We believe that patents and other pr","filed_date":"2016-02-26","accession":"0000886163-16-000149","full_text":"https://origin.rootz.global/static/filing/0000886163-16-000149.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"icle I | | | Liability | Article I | | | Liens | Article I | | | LLC Balance Sheet | Section 3.4 | | | LLC Consolidation | Recitals | | | LLC Documents | Section 3.1(b) | | | Losses | Article I | | | Material Adverse Effect | Article I | | | Merger 1 | Recitals | | | Merger 1 Effective Time | Section 2.2(a) | | | Merger 2 | Recitals | | | Merger 2 Effective Time | Section 2.2(b) | | | Merger Consideration | Article I |","filed_date":"2015-12-18","accession":"0000886163-15-000122","full_text":"https://origin.rootz.global/static/filing/0000886163-15-000122.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"While management believes the Company has provided adequately for its income tax liabilities in its consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition and results of operations.  14 [Table of Contents](#s68DA274DCDD25E51B41520AACE76F6FB) Segment Reporting Under ASC280, Segment Reporting, operating s","filed_date":"2015-11-09","accession":"0000886163-15-000110","full_text":"https://origin.rootz.global/static/filing/0000886163-15-000110.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"While management believes the Company has provided adequately for its income tax liabilities in its consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition and results of operations.  The Company's ending deferred tax liability represents a future tax obligation for current tax amortization claimed on ac","filed_date":"2015-08-05","accession":"0000886163-15-000085","full_text":"https://origin.rootz.global/static/filing/0000886163-15-000085.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"While management believes the Company has provided adequately for its income tax liabilities in its consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition and results of operations.  The Company's ending deferred tax liability represents a future tax obligation for current tax amortization claimed on ac","filed_date":"2015-05-11","accession":"0000886163-15-000062","full_text":"https://origin.rootz.global/static/filing/0000886163-15-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"the option will provide a return to the executive officer only if the market price of the shares appreciates over the option term. Time-based restricted stock unit awards generally vest in equal installments over three years. We also grant performance-based equity awards from time to time and, during 2014, granted performance-based stock options to certain of our named executive officers. In February","filed_date":"2015-03-13","accession":"0001564590-15-001617","full_text":"https://origin.rootz.global/static/filing/0001564590-15-001617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":103,"context":"vesting and were scheduled to vest as follows: 15,000 options would vest if and when cumulative CyDex revenue for 2011 and 2012 exceeded certain pre-determined levels; 25,000 options would vest if we completed a strategic partnership with a commercial partner by June 30, 2012; and 25,000 options would vest if we completed a multi-product CyDex technology-based platform transaction with a pharmaceutical company by June 30, 2012. M","filed_date":"2015-03-13","accession":"0001564590-15-001617","full_text":"https://origin.rootz.global/static/filing/0001564590-15-001617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":11,"context":"gulatory approval can, among other things, result in the suspension of regulatory approval, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us. We are also increasingly subject to regulation by the states. A number of states now regulate, for example, pharmaceutical marketing practices and the reporting of marketing activities, contro","filed_date":"2015-02-23","accession":"0000886163-15-000028","full_text":"https://origin.rootz.global/static/filing/0000886163-15-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"7a60c_7)[](#i0994c61f6f2d4de5b9dd4c746c67a60c_7)[90](#i0994c61f6f2d4de5b9dd4c746c67a60c_7) [5.05](#i0994c61f6f2d4de5b9dd4c746c67a60c_7)[](#i0994c61f6f2d4de5b9dd4c746c67a60c_7)[Financial Statements No Material Adverse Effect.](#i0994c61f6f2d4de5b9dd4c746c67a60c_7)[](#i0994c61f6f2d4de5b9dd4c746c67a60c_7)[90](#i0994c61f6f2d4de5b9dd4c746c67a60c_7) [5.06](#i0994c61f6f2d4de5b9dd4c746c67a60c_7)[](#i0994c61f6f2d4de5b9dd4c746c67","filed_date":"2026-08-07","accession":"0000886163-26-000044","full_text":"https://origin.rootz.global/static/filing/0000886163-26-000044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":99,"match_count":8,"context":"oducts will progress in their development, gain marketing approval or achieve success in the market.In addition, ongoing or future arbitration, or litigation or disputes with third parties may have a material adverse effect on us. Such risks and uncertainties, and others, could cause actual results to differ materially from any future performance suggested. We undertake no obligation to make any revisions to these forwa","filed_date":"2018-05-09","accession":"0000886163-18-000063","full_text":"https://origin.rootz.global/static/filing/0000886163-18-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ns granted to our directors is equal to the fair market value of our common stock on the Nasdaq Global Select Market on the effective date of grant. The initial awards vest in three equal annual installments on each of the first three anniversaries following the date of grant. The annual awards vest in full on the earlier of (1) the date of the annual meeting of our stockholders following the grant d","filed_date":"2022-04-22","accession":"0000886163-22-000038","full_text":"https://origin.rootz.global/static/filing/0000886163-22-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LGND","company":"LIGAND PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"on the option grant date, and no granted option will have a term in excess of 10 years. The shares subject to each option will generally become exercisable for fully-vested shares in a series of installments over a specified period of service measured from the grant date. However, one or more options may be structured so that they are immediately exercisable for any or all of the option shares. The s","filed_date":"2020-11-12","accession":"0001193125-20-291679","full_text":"https://origin.rootz.global/static/filing/0001193125-20-291679.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"18d7fb90ac077c15d2e32043f7e25821ed554019b747621a736f77a62a1a8f8f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"086738382691d9ac2643eaaf7d9bd62549fff9f6ba534e7ea45a596765c0b11e","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":4,"hourly_limit":500,"remaining":496,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}